Relation Therapeutics
PrivateLast Round
Early Funding
Dec 9, 2025
Total Funding Raised
$102.33M
Company Overview
Relation Therapeutics is a biotechnology company that discovers and develops medicines by leveraging its proprietary "Lab-in-the-Loop" platform. The company integrates active-graph machine learning (ML), single-cell multi-omics, and genomic data derived directly from human patient tissue to understand the biology of complex diseases. By generating and interpreting large-scale data, Relation aims to identify novel therapeutic targets and accelerate drug development. The company's initial focus is on osteoporosis, and it has formed strategic collaborations with major pharmaceutical companies like GSK to advance therapeutics in other areas, such as fibrotic diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Relation Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Relation Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Dec 9, 2025 | ||||
| Strategic | Dec 10, 2024 | ||||
| Seed | Mar 14, 2024 | ||||
| Early Stage VC | Jan 19, 2024 | ||||
| Seed | Jun 9, 2022 | ||||
Seed | Jul 1, 2021 |
Key People
Founding team and executive leadership
Relation Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Magnetic Ventures | Early Funding, Seed |
| Deerfield Management | Seed |
| Firstminute Capital | Seed |
| Khosla Ventures | Seed |
| Magnetic Ventures | Seed, Early Funding |
| NVentures | Early Funding |
| The Bill & Melinda Gates Foundation Trust | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 1, 2026
PatchDNA model recognized at NeurIPS AI4D3 workshop.
- Jan 1, 2026
Initiated in 2026 to address fibrosis and osteoarthritis.
Relation Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Relation Therapeutics's valuation, stock price, and market status.
